Pfizer Switzerland’s Pamela Alexa discusses launching Xeljanz (tofacitinib), a treatment for adult patients with moderate to severe active rheumatoid arthritis, building upon Pfizer’s tradition of developing patient-centered therapies. She also discusses supporting research in Switzerland through the Pfizer Research Prize Foundation, which celebrates its 25th anniversary in 2016.
What have been your key priorities since taking over as Pfizer Country Manager in Switzerland in January 2014?
Switzerland provides an excellent environment for pharmaceutical companies to operate in, with a supportive structure that is well organized and has transparent rules and regulations.
